The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Treatment of Lupus Nephritis Continues to See Progress

Treatment of Lupus Nephritis Continues to See Progress

November 23, 2020 • By Thomas R. Collins

  • Tweet
  • Email
Print-Friendly Version / Save PDF

ACR Convergence 2020ACR CONVERGENCE 2020—From exploration of new biomarkers to the benefit of repeat biopsy to the promise of new therapeutics, the treatment of lupus nephritis continues to evolve, three experts said at the ACR Convergence session Lupus Nephritis: New Decade, New Approaches.

You Might Also Like
  • Lupus Nephritis: New Decade, New Approaches
  • Lupus Nephritis Guidelines in Progress
  • Lupus Nephritis: Understanding the Paradigm for Treatment
Also By This Author
  • ANCA-Associated Vasculitis Pathogenesis & Treatment Updates

Dr. Rovin

Benefit of Repeat Biopsies
Brad Rovin, MD, Lee A. Hebert Professor of Nephrology at The Ohio State University Wexner Medical Center, discussed data pointing to benefits of performing biopsies beyond the initial diagnostic biopsy, so they can be used to help guide treatment.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

In the study, 76 patients with lupus nephritis received a maintenance biopsy after the first biopsy, and immunosuppression was continued if histologic activity was present, but discontinued if it was absent.1 If those for whom the therapy was discontinued ended up flaring, induction immunosuppression was restarted.

The process of histologic evaluation and continuation or discontinuation of immunosuppression continued until no patients showed histologic activity.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

After the first repeat biopsy, 21 patients showed histologic activity and continued therapy, and 55 had therapy stopped when no activity was found. Six of those patients experienced a flare.

After the second repeat biopsy, six patients continued therapy and 20 had therapy stopped, which was followed by one flare among those patients. No patients undergoing a third repeat biopsy were found to have histologic activity.

The flare rate among those managed using repeat biopsies was 0.012 per patient year, compared with the 0.059 per patient-year that has been seen among those treated with usual care, Dr. Rovin said. This translates into the need to treat 10 patients under the biopsy-managed protocol to prevent one flare. This may sound like a lot of patients, he acknowledged, but it is not out of line with that seen in many therapeutic trials. Repeat biopsy is clearly useful in helping manage patients, but he cautioned the biopsies should be performed at centers with experience in performing them.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

“I think it’s a little naive to expect the initial histology will be able to predict patient outcomes or prognosis, because prognosis has to be considered in the context of other variables—access to care, adherence to medications, race, ethnicity and, most importantly, response to therapy,” Dr. Rovin said. “Even if we assume the patient is optimally treated, one snapshot of histology really can’t predict the response to therapy.”

Dr. Merrill

Dr. Merrill

Promise of New Therapeutics
Joan Merrill, MD, director of clinical projects in the Arthritis and Clinical Immunology Program at the Oklahoma Medical Research Foundation, Oklahoma City, discussed recent findings from trials of three drugs: the anti-CD20 obinutuzumab, the calcineurin inhibitor voclosporin and the BLyS-inhibitor belimumab.

Pages: 1 2 3 | Single Page

Filed Under: ACR Convergence, Conditions, Meeting Reports, SLE (Lupus) Tagged With: ACR Convergence 2020, Lupus nephritis

You Might Also Like:
  • Lupus Nephritis: New Decade, New Approaches
  • Lupus Nephritis Guidelines in Progress
  • Lupus Nephritis: Understanding the Paradigm for Treatment
  • Precision Medicine for Lupus Continues to Progress

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.